Natixis Advisors LLC Has $1.44 Million Stake in Alkermes plc (NASDAQ:ALKS)

Natixis Advisors LLC raised its holdings in Alkermes plc (NASDAQ:ALKS) by 36.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 49,922 shares of the company’s stock after buying an additional 13,432 shares during the period. Natixis Advisors LLC’s holdings in Alkermes were worth $1,436,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Venturi Wealth Management LLC bought a new stake in Alkermes during the fourth quarter worth about $25,000. EverSource Wealth Advisors LLC raised its stake in shares of Alkermes by 106.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock worth $47,000 after purchasing an additional 842 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Alkermes by 2,231.5% in the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after buying an additional 1,629 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Alkermes by 558.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock valued at $85,000 after buying an additional 2,502 shares in the last quarter. Finally, Cornerstone Investment Partners LLC acquired a new position in Alkermes during the fourth quarter worth $203,000. 95.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. The Goldman Sachs Group lifted their price objective on shares of Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, February 14th. HC Wainwright reiterated a “neutral” rating and set a $46.00 price target on shares of Alkermes in a report on Thursday, February 13th. UBS Group raised Alkermes from a “sell” rating to a “neutral” rating and raised their price objective for the company from $21.00 to $38.00 in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a research note on Tuesday, February 11th. They set a “buy” rating and a $40.00 target price for the company. Finally, Royal Bank of Canada started coverage on Alkermes in a research note on Thursday, March 13th. They issued a “sector perform” rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.46.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 100,918 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the sale, the executive vice president now owns 44,290 shares in the company, valued at approximately $1,419,494.50. This trade represents a 69.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.89% of the stock is owned by company insiders.

Alkermes Stock Down 2.6 %

NASDAQ ALKS opened at $33.88 on Wednesday. The firm has a 50-day moving average price of $33.21 and a two-hundred day moving average price of $30.17. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The company has a market capitalization of $5.51 billion, a P/E ratio of 15.61, a P/E/G ratio of 2.20 and a beta of 0.62.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Equities analysts expect that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.